Thailand's FDA Registers Generic Version Of Abbott's Antiretroviral Aluvia For Use Under Compulsory Licensing Program

Main Category: HIV / AIDS
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 18 Oct 2007 - 12:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:5 stars

5 (2 votes)


Thailand's Food and Drug Administration on Tuesday completed the registration of a generic version of Abbott Laboratories' antiretroviral drug Aluvia for use under the country's compulsory licensing program, the Bangkok Post reports. The generic version is manufactured by Indian pharmaceutical company Matrix Laboratories (Apiradee, Bangkok Post, 10/17). The Thai Ministry of Public Health in June confirmed that it would continue with its plan to issue a compulsory license for the drug after Abbott and the health ministry could not reach a price agreement during negotiations.

The Thai government in January issued a compulsory license to produce a lower-cost version of Abbott's Kaletra. The drug company in May offered to sell Aluvia, an updated version of Kaletra, at a reduced price in Thailand on the condition that the country agreed not to allow generic versions of the drug into the market, Siriwat Thiptaradol, secretary-general of the Thai FDA, said. Abbott offered to sell Aluvia for about 34,000 baht, or $1,000, per person annually. Matrix offered to sell a generic version of Aluvia to Thailand for 24,324 baht, or $695, per person annually (Kaiser Daily HIV/AIDS Report, 6/7).

Vichai Chokewiwat, chair of the Government Pharmaceutical Organization and the health ministry's Committee on Compulsory Licensing, said GPO soon will import the first shipment of the generic version of Aluvia from Matrix. According to Siriwat, the registration process took more than three months to complete. The shipment from Matrix will include enough doses of the drug for 8,000 people during the next six months, the Post reports (Bangkok Post, 10/17).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Kaletra Capsules and Oral Solution.


Article adapted by Medical News Today from original press release.
Visit our hiv / aids section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Thailand's FDA Registers Generic Version Of Abbott's Antiretroviral Aluvia For Use Under Compulsory Licensing Program." Medical News Today. MediLexicon, Intl., 18 Oct. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/85893.php>

APA
Kaiser. (2007, October 18). "Thailand's FDA Registers Generic Version Of Abbott's Antiretroviral Aluvia For Use Under Compulsory Licensing Program." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/85893.php.

Please note: If no author information is provided, the source is cited instead.




HIV / AIDS

Most Popular Articles



Follow Our HIV News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our HIV / AIDS Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »